Literature DB >> 3086239

Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors.

T L Whiteside, S Miescher, J Hurlimann, L Moretta, V von Fliedner.   

Abstract

Tumor-infiltrating lymphocytes (TIL) were obtained by a combination of mechanical release and enzymatic disaggregation from 35 human solid tumors. The number of lymphocytes in TIL-enriched suspensions varied from 1 X 10(4) to 7.6 X 10(6) per wet gram of tumor. The TIL preparations separated by differential centrifugation on Ficoll-Hypaque gradients contained 10-95% of T11+ cells (mean 50%), and tumor cells accounted for the other major cellular component. Macrophages, NK cells, B cells and granulocytes were infrequently seen. Morphologically, TIL-T were small non-activated cells. They expressed the T11 and T3 antigens but not the receptor for IL-2 (IL-2R) or HLA-DR antigens as determined by double immunofluorescence staining. Rare T11+/IL-2R+ cells were recovered only from colon and lung carcinomas. The mean T4/T8 ratio in 12 TIL preparations was 1.1 +/- 0.8. Immunohistology with monoclonal antibodies (MAbs) performed in 31/35 tumors confirmed that the T11+ cells infiltrating solid tumors rarely expressed the IL-2R and that the cell content of suspensions enriched in TIL was comparable to that determined in situ. The recovered TIL were cloned in a microculture system that permits proliferation of nearly all normal peripheral blood T lymphocytes (PBL-T). Under these culture conditions, frequencies of the proliferating T lymphocyte precursors (PTL-P) were depressed in both the TIL preparations (less than 0.01 to 0.39) and patients' PBL-T (0.05 to 0.5). These low frequencies of PTL-P were seen in patients with all tumor types, both primary and metastatic.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086239     DOI: 10.1002/ijc.2910370602

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

1.  Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.

Authors:  T Asai; W J Storkus; T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

3.  Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells.

Authors:  M Radrizzani; C Gambacorti-Passerini; G Parmiani; G Fossati
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  A randomized phase II study of autologous cytokine-induced killer cells in treatment of hepatocellular carcinoma.

Authors:  Xiaozhou Yu; Hua Zhao; Liang Liu; Shui Cao; Baozhu Ren; Naining Zhang; Xiumei An; Jinpu Yu; Hui Li; Xiubao Ren
Journal:  J Clin Immunol       Date:  2013-12-15       Impact factor: 8.317

Review 5.  Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.

Authors:  T L Whiteside; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

6.  Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.

Authors:  E A Grimm; J M Bruner; J Carinhas; J A Köppen; W G Loudon; L Owen-Schaub; P A Steck; R P Moser
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Responses to T cell receptor/CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non-Hodgkin's lymphomas.

Authors:  S Kudoh; Q Wang; O F Hidalgo; P Rayman; R R Tubbs; M G Edinger; V Kolenko; J Panuto; R Bukowski; J H Finke
Journal:  Cancer Immunol Immunother       Date:  1995-09       Impact factor: 6.968

8.  Reduced expression of distinct T-cell CD molecules by collagenase/DNase treatment.

Authors:  W M Mulder; H Koenen; A J van de Muysenberg; E Bloemena; J Wagstaff; R J Scheper
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

9.  Human colorectal tumour infiltrating lymphocytes express activation markers and the CD45RO molecule, showing a primed population of lymphocytes in the tumour area.

Authors:  B Ostenstad; T Lea; E Schlichting; M Harboe
Journal:  Gut       Date:  1994-03       Impact factor: 23.059

10.  In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells.

Authors:  M Stoeck; C Marland-Noske; M Manasterski; R Zawatzky; S Horn; V Möbus; P Schlag; V Schirrmacher
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.